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Abstract 
Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation 
technique increasingly explored for Parkinson’s disease (PD). Although evidence 
is still inconsistent, there are preliminary findings suggesting its efficacy to 
improve motor function in individuals with PD, as the role of secondary motor 
areas remains unclear. The goal of this study was to investigate the effects of left 
dorsolateral prefrontal cortex (DLPFC) tDCS on balance and functional mobility 
of individuals with PD. Seventeen individuals with PD, on-medication, aged 
between 40 and 90 years were recruited to enroll in a double-blind, randomized, 
cross-over trial. Each participant completed two conditions at least 48 hours 
apart, namely anodal-tDCS and sham-tDCS (placebo).The a-tDCS condition 
targeted the left DLPC (F3) and was applied during 20 minutes using a 2 mA 
current intensity.  In the sham-tDCS condition, electrode position remained the 
same but the stimulator was turned off after 30 seconds. Functional mobility and 
balance were assessed using the Berg Balance Scale, Dynamic Gait Index and 
Timed Up and Go. There were significant differences between conditions on all 
outcome measures, as the a-tDCS condition was associated with better 
performance in comparison to the sham condition (p<0.05). Our findings suggest 
that a-tDCS on the left DLPFC improves balance and functional mobility in 
comparison to sham-tDCS. Compensatory mechanisms that support motor 
function in individuals with PD may have been enhanced by a-tDCS on the 
DLPFC, leading to improved functional mobility and balance. Future trials should 
explore left DLPFC stimulation with larger samples and compare t-DCS protocols 
targeting several brain regions. 
Key-words: Parkinson’s disease, transcranial direct current stimulation, non-
invasive brain stimulation, balance, functional mobility 
1. Introduction
Parkinson's disease (PD) is one of the most prevalent neurodegenerative
diseases in the world, with an annual incidence of 4.5 to 19 cases per 100,000 
[1]. PD prevalence is around 0.5-1% in people aged between 65 and 69 years, 
increasing to 1-3% among individuals aged over 80 years [2]. PD is associated 
with the degeneration of dopaminergic neurons of the substantia nigra, hindering 
dopaminergic circuits, especially motor circuits [3, 4]. Thereby, persons with PD 
display several motor symptoms such as rigidity, postural instability, progressive 
bradykinesia, and tremor [5]. Gait impairment is also one of the major motor 
dysfunctions in PD, leading to high levels of disability and poor quality of life [6]. 
The motor symptoms experienced by patients also increase falls and reduce their 
functional independence [5].  
Although drug therapy is the most commonly employed treatment, the 
options in use today only provide symptom relief and do not control or prevent 
disease progression [7]. Moreover, several side effects such as postural 
hypotension, nausea, dyskinesias, and hallucinations are also experienced by 
patients during drug therapy [8]. Thereby, searching for new alternative 
treatments is essential and non-invasive brain stimulation techniques are 
interesting alternatives for PD management. Two meta-analyses have reported 
modest therapeutic effects of high-frequency repetitive transcranial magnetic 
stimulation on motor symptoms of individuals with PD [9, 10]. There is less 
evidence regarding transcranial direct current stimulation (tDCS), but this 
technique has been growingly explored as a therapeutic tool for individuals with 
PD [11]. 
tDCS produces a low electric current over the selected brain areas [12], 
allowing to modify neuronal transmembrane potential, influence excitatory levels 
and modulate firing rates of isolated neuronal cells [13-15].  There are different 
tDCS procedures applied in research: anodal stimulation (a-tDCS), that increases 
cortical excitability of target brain regions; placebo stimulation (sham-tDCS), 
where the stimulator is turned off after a small period of stimulation; and cathodal 
stimulation (c-tDCS), which decreases cortical excitability of target brain regions 
[16].  
Recently, there has been a growing interest on tDCS as a tool to reach 
optimal brain activity, modulate cortical excitability and optimize neuroplastic 
changes, allowing to use this technique as a possible adjunct to rehabilitation. 
Some studies have reported significant positive results of tDCS on motor function 
in PD [11, 17].  However, the systematic review from Elsner et al. (2016) 
comparing active tDCS to sham-tDCS stated that there is no evidence supporting 
the effects of tDCS on gait speed of individuals with PD [18].  
The incongruent findings can be likely explained by the diversity of tDCS 
protocols applied. For instance, stimulus intensity and duration can clearly 
influence the effects on balance and functional mobility [19-21] but few studies 
have been conducted to explore how these variables play a role on tDCS 
response in individuals with PD. Furthermore, the targeted brain areas are also 
a critical factor in tDCS response. Most tDCS studies with individuals with PD 
target the primary motor cortex and although there is increasing knowledge about 
the importance of the primary motor cortex in short- and long-term motor skill 
learning, little is known about the role of secondary motor areas, especially in 
short-term motor performance [22-25]. The prefrontal cortex also seems to play 
a clear role in functional mobility as there are several functional near-infrared 
spectroscopy studies showing that brain activity is increased in this area during 
walking [26, 27]. 
Thereby, the goal of this study was to investigate the effects of left 
dorsolateral prefrontal cortex (DLPFC) a-tDCS on balance and functional mobility 
of individuals with PD.  
2. Materials and Methods
2.1. Participants 
Individuals with PD were recruited from clinics located in Montes Claros 
(Minas Gerais, Brazil) and Rio de Janeiro (Rio de Janeiro, Brazil). To be included 
in the study, participants had to be on an optimal and regular medication regimen 
of levodopa or another antiparkinsonian drug (levodopa equivalent dose greater 
than or equal to 300 mg per day) and be able to walk independently. Participants 
were excluded if they had: cognitive impairment according to Mini-Mental State 
Examination (MMSE) [28]; history of epilepsy; antiparkinsonian drug regimen 
changes during or within three weeks before the experiment; neurological, 
vestibular, visual or psychiatric disorders; cerebral aneurysm; previous surgery 
involving metallic implant. 
Before starting the trial, participants were informed about all experimental 
procedures and signed a written consent form. This study was also approved by 
the Institutional Ethics Committee of the Salgado de Oliveira University 
(#1.591.903). A total of 17 individuals with PD, aged between 50 and 91 years, 
were included in this study. Participants averaged 2.35 ± 1.06 on the Hoehn and 
Yahr scale as well as 18.0 ± 8.96 in the motor domain of the Unified Parkinson’s 
Disease Rating Scale (UPDRS-III). Participants’ sociodemographic and clinical 
characteristics are described at Table 1. 
 
INSERT TABLE 1 HERE 
 
2.2. Experimental Procedure 
 Participants were assessed by an experienced evaluator who completed 
the Hoehn and Yahr staging scale and the UPDRS-III. After the initial screening, 
participants who met the inclusion criteria engaged in a double-blind, 
randomized, cross-over trial, to assess the effects of tDCS on balance and 
functional mobility. Thereby, each participant completed two conditions: a-tDCS 
and sham-tDCS (placebo). The a-tDCS condition targeted the left DLPFC and 
was applied during 20 minutes using a 2 mA current intensity.  In the sham-tDCS 
condition, the participants remained 20 minutes with the electrodes placed in the 
same positions as the a-tDCS condition but the stimulator was turned off after 30 
seconds of active stimulation. To assure that sham-tDCS had no effects on the 
outcome measures, a pilot cross-over study was conducted with 6 individuals 
with PD who completed both sham-tDCS and a control condition (20 minutes of 
sitting). There were no significant differences between both conditions in any of 
the outcomes (p > 0.05), allowing to use of sham-tDCS as a placebo in this trial. 
Experimental conditions were carried at least 48 hours apart (one week 
maximum) to avoid possible carry-over effects. The order of conditions was 
counterbalanced and randomized across participants by a third researcher using 
a website for randomization procedures. In each condition, electrodes were 
removed in the end of each condition in order to complete assessment 
procedures. Outcome measures were then completed by an independent and 
blind evaluator immediately after each condition. Two minutes of rest were 
allowed between each test. 
2.3. tDCS Protocol 
The participants remained comfortably seated in a chair within the 
laboratory. The electric current of 2 mA was applied using a pair of pads soaked 
in saline solution (NaCl 140 mmol dissolved in Milli-Q water) comprising the two 
5x7 cm electrodes [12]. The electrodes (anode and cathode) were connected to 
a continuous current stimulation device with three 9V batteries with a maximum 
output of 10 mA. The batteries were regulated by a digital multimeter (EZA EZ 
984, AU12 China) with a standard error of 1.5. For a-tDCS the anode was placed 
on the left DLPC, located in the electrode area F3 according to the international 
10–20 EEG system [30]. The cathode was placed on the right orbitofrontal cortex 
(Fp2). In the sham-tDCS condition, the electrodes were placed in the same 
positions. However, the stimulator was turned off after 30 seconds, acting as a 
placebo condition. Participants usually report tingling sensations or itching from 
the initial electrical stimulation but there is evidence that there are no stimulation 
effects has the device is turned off during the remaining time [31].This procedure 
allows the subjects to become blinded to the type of stimulus that they will receive 
during the experiment [32]. Both stimulation conditions lasted 20 minutes. 
2.4. Outcome Measures 
All the participants were familiarized with the outcome assessment 
procedures at least a week before testing. The Berg Balance Scale (BBS) was 
used to assess functional balance by rating from 0 (worst) to 4 (best) patients’ 
performance on 14 tasks common to daily living (e.g. seating, turning, picking up 
objects) [33]. The Dynamic Gait Index (DGI) version of De Castro’s et al. [34] was 
used to evaluate functional mobility as it assesses the patients’ ability to adjust 
gait in 8 conditions (e.g. speed change, avoiding objects). Each task was rated 
between 0 (severe impairment) and 3 (normal), allowing for a maximum score of 
24 points, with a score of 19 points or less meaning increased risk of falling [35]. 
The Timed Up and Go (TUG) test was also used to assess functional mobility as 
it has high reliability for individuals with PD [36]. This test measures the time 
needed for the participant to get up from a sitting position, walk a distance of 3 
meters, return, and sit down again (less time equates to better performance). 
 
2.5. Statistical Analysis 
Means and standard deviation were used to report samples characteristics 
and outcome measure data. Several paired t-tests were completed in order to 
compare the outcome measures between conditions. All analysis were performed 
with a significance level of p<0.05, using the statistical pack SPSS 20.0. 
 
3. Results 
 There were not any drop-outs from the trial and all 17 participants were 
included for analysis. Figure 1 presents the comparison between the a-tDCS and 
sham-tDCS conditions on all the outcome measures. There was a significant 
difference between conditions on BBS score (t = - 5.399; p ≤ 0.001), with the a-
tDCS condition displaying better performance (42.82 ± 12.17) in comparison to 
the sham-tDCS (41.06 ± 12.28). There was also a significant difference between 
conditions regarding DGI (t = - 5.607; p ≤ 0.001), with the a-tDCS displaying 
higher scores (16.18 ± 7.48) in comparison to the sham-tDCS (13.88 ± 8.31). 
Finally, there were also significant differences between conditions regarding TUG 
test performance (t = 2.396; p = 0.029). In the a-tDCS condition participants 
completed the test in less time (24.35 ± 18.97) in comparison to the sham-tDCS 
(29.18 ± 24.17). 
INSERT FIG. 1 HERE 
4. Discussion 
The goal of this study was to investigate the effects of a-tDCS on balance 
and functional mobility of individuals with PD. Our findings suggest that a-tDCS 
on the left DLPFC improves balance and functional mobility in comparison to 
sham-tDCS. Findings regarding the effects of tDCS in individuals with PD have 
been fairly inconsistent. A recent systematic review has reported that tDCS may 
reduce motor symptoms in individuals with PD, although there is no sufficient 
data supporting its effects on gait performance [18]. There is even evidence 
suggesting that tDCS does not even enhance other rehabilitation procedures in 
individuals with PD. Costa-Ribeiro et al. [37] analyzed the effects of tDCS 
combined with cueing gait training on functional mobility of individuals with PD. 
The a-tDCS (anode placed in Cz) plus training group displayed similar 
improvements on several gait-related outcome measures in comparison to sham-
tDCS combined with training. 
In contrast, Kaski et al. [23] found a significant benefit of applying a-tDCS 
(2 mA; anode 10%–20% anterior to Cz) during tango dancing, improving trunk 
peak velocity during dancing. Furthermore, there were also modest 
improvements in functional mobility measures as well as an increase in overall 
gait speed and peak pitch trunk speed in comparison to sham-tDCS. Another 
study from this research group tested if combining tDCS in the same brain region 
with physical training could improve gait and balance in individuals with PD [24]. 
Participants performed gait and balance training while completing two stimulation 
conditions, namely 15 minutes of 2 mA a-tDCS in the primary motor and premotor 
cortex) and sham-tDCS. Although participants experienced gait speed 
improvements in both conditions, the effects of combined a-tDCS plus training 
were significantly higher. Furthermore, this study also included a group who 
completed stimulation procedures (a-tDCS and sham) without performing any 
kind of training, with the results showing that there were no isolated benefits of 
tDCS alone on both gait speed and balance. 
Thereby, there is some evidence suggesting that combining tDCS with 
other intervention can maximize effects on balance and functional mobility, but 
the evidence supporting the effects of tDCS alone is lacking. The lack of 
consistent evidence of tDCS may be explained by the different stimulation areas 
chosen by researchers. For instance, Fregni et al. [38] assessed the effects of 
tDCS using different electrode montages and found that a-tDCS in the primary 
motor cortex (C3) improved motor function (simple reaction time), while a-tDCS 
on the dorsolateral prefrontal cortex (F3) had no effects. Benninger et al. [17] 
applied an 8 session a-tDCS protocol to individuals with PD, alternating anode 
position between the pre- and motor cortices (Cz) and the prefrontal cortices. The 
authors reported short-term improvements on gait and bradykinesia in the a-
tDCS group compared to the sham-condition. However, as the authors actively 
stimulated two sites in the protocol, it is not possible to understand which brain 
region underlies the observed improvements. 
It is quite clear that most studies applying tDCS to individuals with PD aim 
to modulate cortical excitability in the primary motor cortex and medial pre-motor 
cortex (supplemental motor area - SMA). SMA is impaired in individuals with PD, 
hindering the internal regulation of movement [25]. This can explain the negative 
findings reported by several authors, as tDCS may not be able to reverse 
disease-related underactivation in this region. However, it is important to highlight 
that abnormal SMA activity is actually compensated by enhanced activity in other 
regions [25, 37, 39]. Thereby, in our study the compensatory mechanisms that 
usually support motor function in individuals with PD may have been enhanced 
by a-tDCS on the dorsolateral prefrontal cortex, leading to improved functional 
mobility and balance. 
There are two possible pathways that can support this hypothesis. First, 
there have been reports supporting the role of the prefrontal cortex in spatial 
orientation [40, 41]. There are also studies highlighting that the prefrontal cortex 
is activated while controlling locomotion in challenging walking conditions [22, 
27]. Thereby, increased excitability on the dorsolateral prefrontal cortex may have 
enhanced visuo-spatial processing, allowing for improved balance and functional 
mobility. Second, lateral premotor areas may have been directly or indirectly 
targeted by tDCS: directly, as placing the anode in the F3 site may also target 
these regions which are anatomically located right next to the dorsolateral 
prefrontal cortex; indirectly because the dorsolateral premotor cortex is 
interconnected with prefrontal areas [42]. This is quite important has the lateral 
premotor areas are the main brain regions who compensate for SMA activity 
impairment [25, 38]. There is also evidence suggesting that the dorsolateral 
premotor cortex plays a clear role in visuo-spatial attention and movement 
anticipation [43], abilities that are critical to efficient balance and functional 
mobility. 
Regardless of the positive findings, the reported trial has several 
limitations. The sample size lacks the power to establish conclusive results 
regarding the effectiveness of tDCS on the left DLPFC to improve balance and 
functional mobility in individuals with PD. Furthermore, it is not possible to state 
that the observed effects were explained by enhanced DLPFC activity has there 
was not an active control condition targeting a brain region that has not been 
related to motor performance and balance. Individuals with PD were also 
assessed during the “on” medication stage and it would be interesting to 
understand if the results could be replicated in the “off” medication phase.  
 
5. Conclusion 
In this trial, a single session of a-tDCS applied on the left DLPFC improved 
balance and functional mobility in individuals with PD in comparison to sham-
tDCS. Future trials should explore left DLPFC stimulation with larger samples and 
compare t-DCS protocols targeting several brain regions, allowing to pinpoint the 
gold-standard tDCS procedures to improve rehabilitation outcomes in individuals 
with PD. Although the literature regarding t-DCS for PD is fairly inconsistent, 
these are promising results and researchers should further explore this technique 
as it has a favorable safety profile, better tolerability, applicability and cost-
effectiveness in comparison to other brain stimulation techniques. 
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Figure legends 
Fig. 1. Acute effects of tDCS on BBS, DGI, and TUG in Parkinson’s disease. 
*Significant difference between the conditions 
 
Table 1. Participants’ characteristics 
Sociodemographic Characteristics 
Gender (male / female) 13 / 4 
Age (years) 69.18 ± 9.98 
Education Level 
Elementary School 
Middle School 
High School 
Higher Education 
 
1 
5 
7 
4 
Clinical Characteristics 
Disease Duration (years) 7.06 ± 2.70 
Hoehn & Yahr Scale 2.35 ± 1.06 
UPDRS-III 18.0 ± 8.96 
Medication 
Levodopa Only 
Levodopa + Dopamine Agonist 
Levodopa + Other 
Other* 
 
7 
4 
5 
1 
Levodopa (mg/day) 635.94 ± 231.66 
Dopamine Agonist LED [mg/day; 29] 87.00 ± 38.11 
Total LED [mg/day; 29] 748.29 ± 343.80 
UPDRS-III: motor domain of the Unified Parkinson’s Disease Rating Scale; LEP: 
Levodopa Equivalent Dose; * Neither levodopa or dopamine agonist. 
 
 
